Cellectis (CLLS) EBT Margin Growth (5y) (2020 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28,096.00 |
| Dec 31, 2025 | -56,297.00 |
| Sep 30, 2025 | 52,893.00 |
| Jun 30, 2025 | 119,944.00 |
| Mar 31, 2025 | -6,566.00 |
| Dec 31, 2024 | 59,452.00 |
| Sep 30, 2024 | 34,266.00 |
| Jun 30, 2024 | 304,212.00 |
| Mar 31, 2024 | 183,938.00 |
| Dec 31, 2023 | -2.81 Mn |
| Sep 30, 2023 | -592,455.00 |
| Jun 30, 2023 | 217,297.00 |
| Mar 31, 2023 | -1.27 Mn |
| Dec 31, 2022 | 38,370.00 |
| Sep 30, 2022 | -1.46 Mn |
| Jun 30, 2022 | -165,492.00 |
| Mar 31, 2022 | -138,063.00 |
| Dec 31, 2021 | 16,920.00 |
| Sep 30, 2021 | -39,524.00 |
| Jun 30, 2021 | 134,269.00 |
| Mar 31, 2021 | 21,472.00 |
| Dec 31, 2020 | -29,059.00 |
| Sep 30, 2020 | -29,811.00 |
| Jun 30, 2020 | -97,353.00 |
| Mar 31, 2020 | 7,097.00 |